|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nature
430:905-908
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of a complex between anthrax toxin and its host cell receptor.
|
|
E.Santelli,
L.A.Bankston,
S.H.Leppla,
R.C.Liddington.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Anthrax toxin consists of the proteins protective antigen (PA), lethal factor
(LF) and oedema factor (EF). The first step of toxin entry into host cells is
the recognition by PA of a receptor on the surface of the target cell.
Subsequent cleavage of receptor-bound PA enables EF and LF to bind and form a
heptameric PA63 pre-pore, which triggers endocytosis. Upon acidification of the
endosome, PA63 forms a pore that inserts into the membrane and translocates EF
and LF into the cytosol. Two closely related host cell receptors, TEM8 and CMG2,
have been identified. Both bind to PA with high affinity and are capable of
mediating toxicity. Here, we report the crystal structure of the PA-CMG2 complex
at 2.5 A resolution. The structure reveals an extensive receptor-pathogen
interaction surface mimicking the non-pathogenic recognition of the
extracellular matrix by integrins. The binding surface is closely conserved in
the two receptors and across species, but is quite different in the integrin
domains, explaining the specificity of the interaction. CMG2 engages two domains
of PA, and modelling of the receptor-bound PA63 heptamer suggests that the
receptor acts as a pH-sensitive brace to ensure accurate and timely membrane
insertion. The structure provides new leads for the discovery of anthrax
anti-toxins, and should aid the design of cancer therapeutics.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1: Structure of the PA -CMG2 complex. Two orthogonal
views are shown in ribbon representation. PA is coloured by
domain (I -IV). CMG2 is blue; the metal ion is shown as a
magenta ball. PA domain I is cleaved after receptor binding,
leading to the loss of domain Ia (yellow) and the formation of
PA[63]. All molecular graphics images were generated using the
UCSF Chimera package^29 (http://www.cgl.ucsf.edu/chimera).
|
 |
Figure 5.
Figure 5: Hypothetical model of the receptor-bound,
membrane-inserted PA pore. The model is based on the pre-pore
PA[63] crystal structure^6, channel conductance studies8, and
the crystal structure of -haemolysin19.
The barrel is formed by rearrangement in each monomer of the
segment shown in red in Fig. 3. Each PA[63] monomer is shown in
a different colour. Residues 303 -324 form the membrane-spanning
region of the barrel. Seven copies of the CMG2 I domain bound to
the heptamer are in blue. The 40
Å gap between the CMG2 I domain and the membrane may be occupied
by a 100-residue
domain of CMG2, C-terminal to the I domain, which precedes its
membrane-spanning sequence.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nature
(2004,
430,
905-908)
copyright 2004.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.F.Kintzer,
H.J.Sterling,
I.I.Tang,
E.R.Williams,
and
B.A.Krantz
(2010).
Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism.
|
| |
PLoS One,
5,
e13888.
|
 |
|
|
|
|
 |
M.Martchenko,
S.Y.Jeong,
and
S.N.Cohen
(2010).
Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin.
|
| |
Proc Natl Acad Sci U S A,
107,
15583-15588.
|
 |
|
|
|
|
 |
M.Radjainia,
J.K.Hyun,
C.E.Leysath,
S.H.Leppla,
and
A.K.Mitra
(2010).
Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex.
|
| |
Proc Natl Acad Sci U S A,
107,
14070-14074.
|
 |
|
|
|
|
 |
N.London,
B.Raveh,
D.Movshovitz-Attias,
and
O.Schueler-Furman
(2010).
Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions?
|
| |
Proteins,
78,
3140-3149.
|
 |
|
|
|
|
 |
S.Dutta,
B.Mazumdar,
K.K.Banerjee,
and
A.N.Ghosh
(2010).
Three-dimensional structure of different functional forms of the Vibrio cholerae hemolysin oligomer: a cryo-electron microscopic study.
|
| |
J Bacteriol,
192,
169-178.
|
 |
|
|
|
|
 |
S.Fu,
X.Tong,
C.Cai,
Y.Zhao,
Y.Wu,
Y.Li,
J.Xu,
X.C.Zhang,
L.Xu,
W.Chen,
and
Z.Rao
(2010).
The structure of tumor endothelial marker 8 (TEM8) extracellular domain and implications for its receptor function for recognizing anthrax toxin.
|
| |
PLoS One,
5,
e11203.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.F.Kintzer,
K.L.Thoren,
H.J.Sterling,
K.C.Dong,
G.K.Feld,
I.I.Tang,
T.T.Zhang,
E.R.Williams,
J.M.Berger,
and
B.A.Krantz
(2009).
The protective antigen component of anthrax toxin forms functional octameric complexes.
|
| |
J Mol Biol,
392,
614-629.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.S.Williams,
S.Lovell,
A.Anbanandam,
R.El-Chami,
and
J.G.Bann
(2009).
Domain 4 of the anthrax protective antigen maintains structure and binding to the host receptor CMG2 at low pH.
|
| |
Protein Sci,
18,
2277-2286.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.D.Kelly-Cirino,
and
N.J.Mantis
(2009).
Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.
|
| |
Infect Immun,
77,
4859-4867.
|
 |
|
|
|
|
 |
C.E.Leysath,
A.F.Monzingo,
J.A.Maynard,
J.Barnett,
G.Georgiou,
B.L.Iverson,
and
J.D.Robertus
(2009).
Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen.
|
| |
J Mol Biol,
387,
680-693.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.Reason,
J.Liberato,
J.Sun,
W.Keitel,
and
J.Zhou
(2009).
Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed.
|
| |
Infect Immun,
77,
2030-2035.
|
 |
|
|
|
|
 |
G.van der Goot,
and
J.A.Young
(2009).
Receptors of anthrax toxin and cell entry.
|
| |
Mol Aspects Med,
30,
406-412.
|
 |
|
|
|
|
 |
J.N.Tournier,
R.G.Ulrich,
A.Quesnel-Hellmann,
M.Mohamadzadeh,
and
B.G.Stiles
(2009).
Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
|
| |
Expert Rev Anti Infect Ther,
7,
219-236.
|
 |
|
|
|
|
 |
M.Rajapaksha,
J.F.Eichler,
J.Hajduch,
D.E.Anderson,
K.L.Kirk,
and
J.G.Bann
(2009).
Monitoring anthrax toxin receptor dissociation from the protective antigen by NMR.
|
| |
Protein Sci,
18,
17-23.
|
 |
|
|
|
|
 |
M.Y.Go,
E.M.Chow,
and
J.Mogridge
(2009).
The cytoplasmic domain of anthrax toxin receptor 1 affects binding of the protective antigen.
|
| |
Infect Immun,
77,
52-59.
|
 |
|
|
|
|
 |
N.Abboud,
M.De Jesus,
A.Nakouzi,
R.J.Cordero,
M.Pujato,
A.Fiser,
J.Rivera,
and
A.Casadevall
(2009).
Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies.
|
| |
J Biol Chem,
284,
25077-25086.
|
 |
|
|
|
|
 |
Q.Li,
K.K.Peachman,
L.Sower,
S.H.Leppla,
S.B.Shivachandra,
G.R.Matyas,
J.W.Peterson,
C.R.Alving,
M.Rao,
and
V.B.Rao
(2009).
Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.
|
| |
Open Vaccine J,
2,
92-99.
|
 |
|
|
|
|
 |
R.J.Collier
(2009).
Membrane translocation by anthrax toxin.
|
| |
Mol Aspects Med,
30,
413-422.
|
 |
|
|
|
|
 |
S.Sharma,
D.Thomas,
J.Marlett,
M.Manchester,
and
J.A.Young
(2009).
Efficient neutralization of antibody-resistant forms of anthrax toxin by a soluble receptor decoy inhibitor.
|
| |
Antimicrob Agents Chemother,
53,
1210-1212.
|
 |
|
|
|
|
 |
A.Sivasubramanian,
J.A.Maynard,
and
J.J.Gray
(2008).
Modeling the structure of mAb 14B7 bound to the anthrax protective antigen.
|
| |
Proteins,
70,
218-230.
|
 |
|
|
|
|
 |
D.C.Reason,
A.Ullal,
J.Liberato,
J.Sun,
W.Keitel,
and
J.Zhou
(2008).
Domain specificity of the human antibody response to Bacillus anthracis protective antigen.
|
| |
Vaccine,
26,
4041-4047.
|
 |
|
|
|
|
 |
K.Bandurska,
R.Brodzik,
S.Spitsin,
T.Kohl,
C.Portocarrero,
Y.Smirnov,
N.Pogrebnyak,
A.Sirko,
H.Koprowski,
and
M.Golovkin
(2008).
Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4.
|
| |
Hybridoma (Larchmt),
27,
241-247.
|
 |
|
|
|
|
 |
M.Madegowda,
S.Eswaramoorthy,
S.K.Burley,
and
S.Swaminathan
(2008).
X-ray crystal structure of the B component of Hemolysin BL from Bacillus cereus.
|
| |
Proteins,
71,
534-540.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Vuyisich,
S.Gnanakaran,
J.A.Lovchik,
C.R.Lyons,
and
G.Gupta
(2008).
A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax.
|
| |
Protein J,
27,
292-302.
|
 |
|
|
|
|
 |
M.Yan,
M.H.Roehrl,
E.Basar,
and
J.Y.Wang
(2008).
Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
|
| |
Vaccine,
26,
947-955.
|
 |
|
|
|
|
 |
D.G.Bouzianas
(2007).
Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism.
|
| |
Expert Rev Anti Infect Ther,
5,
665-684.
|
 |
|
|
|
|
 |
D.J.Manayani,
D.Thomas,
K.A.Dryden,
V.Reddy,
M.E.Siladi,
J.M.Marlett,
G.J.Rainey,
M.E.Pique,
H.M.Scobie,
M.Yeager,
J.A.Young,
M.Manchester,
and
A.Schneemann
(2007).
A viral nanoparticle with dual function as an anthrax antitoxin and vaccine.
|
| |
PLoS Pathog,
3,
1422-1431.
|
 |
|
|
|
|
 |
H.M.Scobie,
J.M.Marlett,
G.J.Rainey,
D.B.Lacy,
R.J.Collier,
and
J.A.Young
(2007).
Anthrax toxin receptor 2 determinants that dictate the pH threshold of toxin pore formation.
|
| |
PLoS ONE,
2,
e329.
|
 |
|
|
|
|
 |
J.A.Young,
and
R.J.Collier
(2007).
Anthrax toxin: receptor binding, internalization, pore formation, and translocation.
|
| |
Annu Rev Biochem,
76,
243-265.
|
 |
|
|
|
|
 |
J.Hong,
R.C.Doebele,
M.W.Lingen,
L.A.Quilliam,
W.J.Tang,
and
M.R.Rosner
(2007).
Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1.
|
| |
J Biol Chem,
282,
19781-19787.
|
 |
|
|
|
|
 |
J.Mogridge
(2007).
Defensive strategies of Bacillus anthracis that promote a fatal disease.
|
| |
Drug Discov Today Dis Mech,
4,
253-258.
|
 |
|
|
|
|
 |
J.Sun,
G.Vernier,
D.J.Wigelsworth,
and
R.J.Collier
(2007).
Insertion of anthrax protective antigen into liposomal membranes: effects of a receptor.
|
| |
J Biol Chem,
282,
1059-1065.
|
 |
|
|
|
|
 |
K.A.Rmali,
M.C.Puntis,
and
W.G.Jiang
(2007).
Tumour-associated angiogenesis in human colorectal cancer.
|
| |
Colorectal Dis,
9,
3.
|
 |
|
|
|
|
 |
K.H.Chen,
S.Liu,
L.A.Bankston,
R.C.Liddington,
and
S.H.Leppla
(2007).
Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.
|
| |
J Biol Chem,
282,
9834-9845.
|
 |
|
|
|
|
 |
L.Xu,
and
D.M.Frucht
(2007).
Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses.
|
| |
Int J Biochem Cell Biol,
39,
20-24.
|
 |
|
|
|
|
 |
R.V.Kolla,
S.Chintalapati,
M.Sabet,
E.Santelli,
R.C.Liddington,
M.David,
J.Fierer,
D.Guiney,
and
R.C.Rickert
(2007).
Complement c3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response.
|
| |
PLoS ONE,
2,
e1044.
|
 |
|
|
|
|
 |
S.Liu,
H.J.Leung,
and
S.H.Leppla
(2007).
Characterization of the interaction between anthrax toxin and its cellular receptors.
|
| |
Cell Microbiol,
9,
977-987.
|
 |
|
|
|
|
 |
A.E.Gerdon,
D.W.Wright,
and
D.E.Cliffel
(2006).
Epitope mapping of the protective antigen of B. anthracis by using nanoclusters presenting conformational peptide epitopes.
|
| |
Angew Chem Int Ed Engl,
45,
594-598.
|
 |
|
|
|
|
 |
A.G.Remacle,
D.V.Rozanov,
M.Fugere,
R.Day,
and
A.Y.Strongin
(2006).
Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP.
|
| |
Oncogene,
25,
5648-5655.
|
 |
|
|
|
|
 |
D.J.Stearns-Kurosawa,
F.Lupu,
F.B.Taylor,
G.Kinasewitz,
and
S.Kurosawa
(2006).
Sepsis and pathophysiology of anthrax in a nonhuman primate model.
|
| |
Am J Pathol,
169,
433-444.
|
 |
|
|
|
|
 |
F.Tama,
G.Ren,
C.L.Brooks,
and
A.K.Mitra
(2006).
Model of the toxic complex of anthrax: responsive conformational changes in both the lethal factor and the protective antigen heptamer.
|
| |
Protein Sci,
15,
2190-2200.
|
 |
|
|
|
|
 |
H.M.Scobie,
D.J.Wigelsworth,
J.M.Marlett,
D.Thomas,
G.J.Rainey,
D.B.Lacy,
M.Manchester,
R.J.Collier,
and
J.A.Young
(2006).
Anthrax toxin receptor 2-dependent lethal toxin killing in vivo.
|
| |
PLoS Pathog,
2,
e111.
|
 |
|
|
|
|
 |
H.M.Scobie,
and
J.A.Young
(2006).
Divalent metal ion coordination by residue T118 of anthrax toxin receptor 2 is not essential for protective antigen binding.
|
| |
PLoS ONE,
1,
e99.
|
 |
|
|
|
|
 |
I.I.Salles,
D.E.Voth,
S.C.Ward,
K.M.Averette,
R.K.Tweten,
K.A.Bradley,
and
J.D.Ballard
(2006).
Cytotoxic activity of Bacillus anthracis protective antigen observed in a macrophage cell line overexpressing ANTXR1.
|
| |
Cell Microbiol,
8,
1272-1281.
|
 |
|
|
|
|
 |
J.F.Kuhn,
P.Hoerth,
S.T.Hoehn,
T.Preckel,
and
K.B.Tomer
(2006).
Proteomics study of anthrax lethal toxin-treated murine macrophages.
|
| |
Electrophoresis,
27,
1584-1597.
|
 |
|
|
|
|
 |
J.Rivera,
A.Nakouzi,
N.Abboud,
E.Revskaya,
D.Goldman,
R.J.Collier,
E.Dadachova,
and
A.Casadevall
(2006).
A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1.
|
| |
Infect Immun,
74,
4149-4156.
|
 |
|
|
|
|
 |
J.W.Peterson,
J.E.Comer,
D.M.Noffsinger,
A.Wenglikowski,
K.G.Walberg,
B.M.Chatuev,
A.K.Chopra,
L.R.Stanberry,
A.S.Kang,
W.W.Scholz,
and
J.Sircar
(2006).
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.
|
| |
Infect Immun,
74,
1016-1024.
|
 |
|
|
|
|
 |
M.E.Smith,
M.Koser,
S.Xiao,
C.Siler,
J.P.McGettigan,
C.Calkins,
R.J.Pomerantz,
B.Dietzschold,
and
M.J.Schnell
(2006).
Rabies virus glycoprotein as a carrier for anthrax protective antigen.
|
| |
Virology,
353,
344-356.
|
 |
|
|
|
|
 |
M.Gao,
and
K.Schulten
(2006).
Onset of anthrax toxin pore formation.
|
| |
Biophys J,
90,
3267-3279.
|
 |
|
|
|
|
 |
M.J.Gubbins,
J.D.Berry,
C.R.Corbett,
J.Mogridge,
X.Y.Yuan,
L.Schmidt,
B.Nicolas,
A.Kabani,
and
R.S.Tsang
(2006).
Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen.
|
| |
FEMS Immunol Med Microbiol,
47,
436-443.
|
 |
|
|
|
|
 |
M.J.McConnell,
P.C.Hanna,
and
M.J.Imperiale
(2006).
Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.
|
| |
Infect Immun,
74,
1009-1015.
|
 |
|
|
|
|
 |
M.J.McConnell,
X.Danthinne,
and
M.J.Imperiale
(2006).
Characterization of a permissive epitope insertion site in adenovirus hexon.
|
| |
J Virol,
80,
5361-5370.
|
 |
|
|
|
|
 |
R.A.Melnyk,
and
R.J.Collier
(2006).
A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformation.
|
| |
Proc Natl Acad Sci U S A,
103,
9802-9807.
|
 |
|
|
|
|
 |
R.Mabry,
K.Brasky,
R.Geiger,
R.Carrion,
G.B.Hubbard,
S.Leppla,
J.L.Patterson,
G.Georgiou,
and
B.L.Iverson
(2006).
Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays.
|
| |
Clin Vaccine Immunol,
13,
671-677.
|
 |
|
|
|
|
 |
S.Basha,
P.Rai,
V.Poon,
A.Saraph,
K.Gujraty,
M.Y.Go,
S.Sadacharan,
M.Frost,
J.Mogridge,
and
R.S.Kane
(2006).
Polyvalent inhibitors of anthrax toxin that target host receptors.
|
| |
Proc Natl Acad Sci U S A,
103,
13509-13513.
|
 |
|
|
|
|
 |
S.J.Tilley,
and
H.R.Saibil
(2006).
The mechanism of pore formation by bacterial toxins.
|
| |
Curr Opin Struct Biol,
16,
230-236.
|
 |
|
|
|
|
 |
T.A.Springer
(2006).
Complement and the multifaceted functions of VWA and integrin I domains.
|
| |
Structure,
14,
1611-1616.
|
 |
|
|
|
|
 |
B.A.Aulinger,
M.H.Roehrl,
J.J.Mekalanos,
R.J.Collier,
and
J.Y.Wang
(2005).
Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.
|
| |
Infect Immun,
73,
3408-3414.
|
 |
|
|
|
|
 |
G.J.Rainey,
D.J.Wigelsworth,
P.L.Ryan,
H.M.Scobie,
R.J.Collier,
and
J.A.Young
(2005).
Receptor-specific requirements for anthrax toxin delivery into cells.
|
| |
Proc Natl Acad Sci U S A,
102,
13278-13283.
|
 |
|
|
|
|
 |
G.Zomber,
S.Reuveny,
N.Garti,
A.Shafferman,
and
E.Elhanany
(2005).
Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen.
|
| |
J Biol Chem,
280,
39897-39906.
|
 |
|
|
|
|
 |
H.M.Scobie,
and
J.A.Young
(2005).
Interactions between anthrax toxin receptors and protective antigen.
|
| |
Curr Opin Microbiol,
8,
106-112.
|
 |
|
|
|
|
 |
J.C.Burnett,
E.A.Henchal,
A.L.Schmaljohn,
and
S.Bavari
(2005).
The evolving field of biodefence: therapeutic developments and diagnostics.
|
| |
Nat Rev Drug Discov,
4,
281-297.
|
 |
|
|
|
|
 |
J.F.Eichler,
J.C.Cramer,
K.L.Kirk,
and
J.G.Bann
(2005).
Biosynthetic incorporation of fluorohistidine into proteins in E. coli: a new probe of macromolecular structure.
|
| |
Chembiochem,
6,
2170-2173.
|
 |
|
|
|
|
 |
J.T.Wolfe,
B.A.Krantz,
G.J.Rainey,
J.A.Young,
and
R.J.Collier
(2005).
Whole-cell voltage clamp measurements of anthrax toxin pore current.
|
| |
J Biol Chem,
280,
39417-39422.
|
 |
|
|
|
|
 |
J.Y.Wang,
and
M.H.Roehrl
(2005).
Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin.
|
| |
Med Immunol,
4,
4.
|
 |
|
|
|
|
 |
L.Abrami,
N.Reig,
and
F.G.van der Goot
(2005).
Anthrax toxin: the long and winding road that leads to the kill.
|
| |
Trends Microbiol,
13,
72-78.
|
 |
|
|
|
|
 |
M.M.Numa,
L.V.Lee,
C.C.Hsu,
K.E.Bower,
and
C.H.Wong
(2005).
Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ.
|
| |
Chembiochem,
6,
1002-1006.
|
 |
|
|
|
|
 |
R.J.Gilbert
(2005).
Inactivation and activity of cholesterol-dependent cytolysins: what structural studies tell us.
|
| |
Structure,
13,
1097-1106.
|
 |
|
|
|
|
 |
R.Mabry,
M.Rani,
R.Geiger,
G.B.Hubbard,
R.Carrion,
K.Brasky,
J.L.Patterson,
G.Georgiou,
and
B.L.Iverson
(2005).
Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region.
|
| |
Infect Immun,
73,
8362-8368.
|
 |
|
|
|
|
 |
R.N.Brey
(2005).
Molecular basis for improved anthrax vaccines.
|
| |
Adv Drug Deliv Rev,
57,
1266-1292.
|
 |
|
|
|
|
 |
J.G.Bann,
and
S.J.Hultgren
(2004).
Structural biology: anthrax hijacks host receptor.
|
| |
Nature,
430,
843-844.
|
 |
|
|
|
|
 |
S.Zhang,
A.Finkelstein,
and
R.J.Collier
(2004).
Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel.
|
| |
Proc Natl Acad Sci U S A,
101,
16756-16761.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |